According to the company, IMG-7289 is a small molecule developed by inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression in
hematopoietic cells.
I will apply state-of-the-art techniques, Including genetic fate tracing experiments, Conditional genetic knockout mouse models, Tissue engineering of the bone marrow niche and in vivo and in vitro crispr/cas9 gene editing, To unravel the complex molecular and cellular interaction between fibrosis-causing cells and the malignant
hematopoietic cells.
Converting adult human vascular endothelial cells into
hematopoietic cells has been proven feasible.
The aim of this study was to evaluate the possible changes in miRNA expression profiles in CD133 (+)
hematopoietic cells after in vitro culture.
Stem cells are the progenitors of all
hematopoietic cells that generate red and white blood cells and blood platelets.
At the microscopic level, the lesions were composed of mature adipose tissue,
hematopoietic cells and hyperplasia of zona reticularis of adrenal cortex.
Alessandra Biffi, who headed the metachromatic leukodystrophy trial, added: "The corrected
hematopoietic cells reach the brain through the blood and release the correct protein that is 'gathered' there by the surrounding nerve cells.
Mount Sinai researchers screened a panel of 18 genetic factors for inducing blood-forming activity and identified a combination of four transcription factors, Gata2, Gfi1b, cFos, and Etv6 as sufficient to generate blood vessel precursor cells with the subsequent appearance of
hematopoietic cells.
Other than the small fraction of endothelial cell lineage that primarily forms the marrow vasculature, cells in the bone marrow can be compartmentalized into 2 types with respect to their origins, as mesenchymal and
hematopoietic cells.
The company says the trial resulted in accelerated neutrophil and platelet recoveries, together with excellent 100-day patient survival and low GVHD rates in patients receiving partially mismatched
hematopoietic cells from umbilical cord blood expanded by Mesoblast's proprietary allogeneic mesenchymal precursor cells (MPCs).
The Phase 3 trial will aim to reproduce the positive pilot trial results seen at the University of Texas MD Anderson Cancer, where accelerated neutrophil and platelet recoveries, together with excellent 100-day patient survival and low GVHD rates, occurred in patients receiving partially mismatched
hematopoietic cells from umbilical cord blood expanded by Mesoblast's proprietary allogeneic or "off-the-shelf" mesenchymal precursor cells (MPCs).
1) An alternative hypothesis, at least for patients with infiltrative diseases of the bone marrow, is that alteration of the bone marrow microenvironment leads to premature exit of immature
hematopoietic cells from the bone marrow, with their accumulation at extramedullary anatomic sites.
